Merus N.V.
MRUS
Cena:
$ 90.00
0.00 (0.00%)
Valuace
70
Růst
0
Zdraví
75
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
MERUS POWER DELIVERS AN ENERGY STORAGE SYSTEM FOR EXTREME ARCTIC CONDITIONS
11-02-2026
YLÖJÄRVI, FINLAND--(BUSINESS WIRE)--MERUS POWER OYJ HAS SIGNED A BATTERY ENERGY STORAGE DEAL WORTH...
Více zde
GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD
12-12-2025
COPENHAGEN, DENMARK--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) (“GENMAB”) ANNOUNCED TODAY THAT ...
Více zde
GENMAB ANNOUNCES COMPLETION OF TENDER OFFER FOR OUTSTANDING COMMON SHARES OF MERUS N.V. AND COMMENCEMENT OF SUBSEQUENT OFFERING PERIOD
12-12-2025
COMPANY ANNOUNCEMENT TRANSACTION ADDS PETOSEMTAMAB, A LATE-STAGE ASSET WITH TWO BREAKTHROUGH THERAPY...
Více zde
MERUS AND HALOZYME ENTER GLOBAL COLLABORATION AND LICENSE AGREEMENT TO DEVELOP SUBCUTANEOUS FORMULATION OF PETOSEMTAMAB
17-11-2025
SAN DIEGO AND UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS. , NOV. 17, 2025 /PRNEWSWIRE/ -- MERUS N....
Více zde
MERUS' INTERIM DATA ON PETOSEMTAMAB IN METASTATIC COLORECTAL CANCER DEMONSTRATES MONOTHERAPY ACTIVITY AND ROBUST RESPONSE RATE IN COMBINATION WITH FOLFOX/FOLFIRI WITH WELL TOLERATED SAFETY
24-10-2025
– 100% RESPONSE RATE IN 1L LEFT-SIDED MCRC (N=8, CONFIRMED AND UNCONFIRMED) – 62% RESPONSE RATE ...
Více zde
MERUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF MERUS N.V. - MRUS
23-10-2025
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ...
Více zde
GENMAB COMMENCES TENDER OFFER FOR ALL ISSUED AND OUTSTANDING COMMON SHARES OF MERUS N.V.
21-10-2025
MEDIA RELEASE COPENHAGEN, DENMARK; OCTOBER 21, 2025 GENMAB A/S (NASDAQ: G MAB ) (“GENMAB”) ANNOU...
Více zde
MERUS ANNOUNCES PUBLICATION OF AN ABSTRACT ON PETOSEMTAMAB IN METASTATIC COLORECTAL CANCER AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
14-10-2025
- PETOSEMTAMAB IN COMBINATION WITH FOLFOX /FOLFIRI (1L AND 2L MCRC) AND AS MONOTHERAPY (3L+ MCRC), D...
Více zde
MERUS ANNOUNCES PETOSEMTAMAB IN METASTATIC COLORECTAL CANCER ABSTRACT SELECTED FOR PLENARY SESSION ORAL PRESENTATION AT THE AACR-NCI-EORTC INTERNATIONAL CONFERENCE ON MOLECULAR TARGETS AND CANCER THERAPEUTICS
13-10-2025
- PLENARY SESSION ORAL PRESENTATION: FRIDAY, OCTOBER 24 10:00 -11:40 A.M. ET - POSTER PRESEN...
Více zde
SHAREHOLDER INVESTIGATION: HALPER SADEH LLC INVESTIGATES EA AND MRUS ON BEHALF OF SHAREHOLDERS
01-10-2025
NEW YORK, OCT. 01, 2025 (GLOBE NEWSWIRE) -- HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVEST...
Více zde
MERUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF MERUS N.V. - MRUS
30-09-2025
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ...
Více zde
$HAREHOLDER ALERT: THE M&A CLASS ACTION FIRM ANNOUNCES AN INVESTIGATION OF 1ST MERUS N.V. (NASDAQ: MRUS)
30-09-2025
NEW YORK , SEPT. 30, 2025 /PRNEWSWIRE/ -- CLASS ACTION ATTORNEY JUAN MONTEVERDE WITH MONTEVERDE & ...
Více zde
MRUS STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF MERUS N.V. IS FAIR TO SHAREHOLDERS
29-09-2025
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde
GENMAB TO ACQUIRE MERUS, EXPANDING LATE-STAGE PIPELINE AND ACCELERATING INTO A WHOLLY OWNED MODEL
29-09-2025
COPENHAGEN, DENMARK & UTRECHT, NETHERLANDS--(BUSINESS WIRE)--GENMAB A/S (NASDAQ: GMAB) AND MERUS N.V...
Více zde
GENMAB TO ACQUIRE MERUS, EXPANDING LATE-STAGE PIPELINE AND ACCELERATING INTO A WHOLLY OWNED MODEL
29-09-2025
COMPANY ANNOUNCEMENT GENMAB TO ACQUIRE MERUS FOR USD 97.00 PER SHARE IN AN ALL-CASH TRANSACTION REPR...
Více zde
MERUS TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
28-08-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., AUG. 28, 2025 (GLOBE NEWSWIRE) -- MERUS N.V....
Více zde
MERUS TO PRESENT AT THE CANACCORD GENUITY 45TH ANNUAL GROWTH CONFERENCE
06-08-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., AUG. 06, 2025 (GLOBE NEWSWIRE) -- MERUS N.V. (NASDAQ:...
Více zde
MERUS ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 AND PROVIDES BUSINESS UPDATE
05-08-2025
- PETOSEMTAMAB IN COMBINATION WITH PEMBROLIZUMAB IN 1L PD-L1+ R/M HNSCC PHASE 2 TRIAL DEMONSTRATES 6...
Více zde
MERUS N.V. REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
04-08-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., AUG. 04, 2025 (GLOBE NEWSWIRE) -- MERUS N.V. (NASDAQ...
Více zde
MERUS GLOBAL INVESTMENTS STRENGTHENS LEADERSHIP AND EXPANDS TALENT BENCH WITH STRATEGIC HIRES AND KEY PROMOTIONS
23-07-2025
NEW YORK--(BUSINESS WIRE)--MERUS GLOBAL INVESTMENTS (“MERUS”), A MULTI-STRATEGY INVESTMENT PARTN...
Více zde
MERUS N.V. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES
04-06-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., JUNE 04, 2025 (GLOBE NEWSWIRE) -- MERUS N.V. (NASDAQ:...
Více zde
MERUS N.V. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
03-06-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- MERUS N.V....
Více zde
MERUS TO PRESENT AT UPCOMING INVESTOR CONFERENCES
27-05-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., MAY 27, 2025 (GLOBE NEWSWIRE) -- MERUS N.V....
Více zde
MERUS' PETOSEMTAMAB WITH PEMBROLIZUMAB INTERIM DATA DEMONSTRATES ROBUST EFFICACY AND DURABILITY IN 1L PD-L1+ R/M HNSCC
22-05-2025
- 63% RESPONSE RATE OBSERVED AMONG 43 EVALUABLE PATIENTS - 79% OVERALL SURVIVAL RATE AT 12-MONTH...
Více zde
MERUS ANNOUNCES THE JOURNAL PUBLICATION OF PETOSEMTAMAB MECHANISM OF ACTION
15-05-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., MAY 15, 2025 (GLOBE NEWSWIRE) -- MERUS N.V....
Více zde
MERUS TO PRESENT AT BOFA SECURITIES 2025 HEALTH CARE CONFERENCE
08-05-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., MAY 08, 2025 (GLOBE NEWSWIRE) -- MERUS N.V....
Více zde
MERUS ANNOUNCES FINANCIAL RESULTS FOR THE FIRST QUARTER 2025 AND PROVIDES BUSINESS UPDATE
07-05-2025
- PETOSEMTAMAB IN COMBINATION WITH PEMBROLIZUMAB IN 1L PD-L1+ R/M HNSCC PHASE 2 TRIAL ONGOING WITH C...
Více zde
MERUS ANNOUNCES ABSTRACT ACCEPTED FOR PRESENTATION AT THE 2025 ASCO® ANNUAL MEETING
23-04-2025
- PETOSEMTAMAB IN COMBINATION WITH PEMBROLIZUMAB IN 1L PD-L1+ R/M HNSCC INTERIM CLINICAL DATA SELECT...
Více zde
MERUS TO PARTICIPATE IN A FIRESIDE CHAT AT THE 24TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
01-04-2025
UTRECHT, THE NETHERLANDS AND CAMBRIDGE, MASS., APRIL 01, 2025 (GLOBE NEWSWIRE) -- MERUS N.V. (NASDAQ...
Více zde
MERUS ANNOUNCES FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2024 AND PROVIDES BUSINESS UPDATE
27-02-2025
- PHASE 3 REGISTRATIONAL TRIALS EVALUATING PETOSEMTAMAB IN COMBINATION WITH PEMBROLIZUMAB IN 1L PD...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2025-12-30 00:00:00 | 8-K |  | Stáhnout |
| 2025-12-12 00:00:00 | 8-K | | Stáhnout |
| 2025-12-09 00:00:00 | 8-K | | Stáhnout |
| 2025-10-31 00:00:00 | 10-Q | | Stáhnout |
| 2025-09-29 01:00:00 | 8-K | | Stáhnout |
| 2025-09-29 00:00:00 | 8-K | | Stáhnout |
| 2025-08-05 01:00:00 | 10-Q | | Stáhnout |
| 2025-08-05 00:00:00 | 10-Q | | Stáhnout |
| 2025-06-05 01:00:00 | 8-K | | Stáhnout |
| 2025-06-05 00:00:00 | 8-K | | Stáhnout |
| 2025-05-29 01:00:00 | 8-K | | Stáhnout |
| 2025-05-29 00:00:00 | 8-K | | Stáhnout |
| 2025-05-22 01:00:00 | 8-K | | Stáhnout |
| 2025-05-22 00:00:00 | 8-K | | Stáhnout |
| 2025-05-07 01:00:00 | 10-Q | | Stáhnout |
| 2025-05-07 00:00:00 | 10-Q | | Stáhnout |
| 2025-02-27 00:00:00 | 10-K | | Stáhnout |
| 2025-02-26 23:00:00 | 10-K | | Stáhnout |
| 2024-12-05 00:00:00 | 8-K | | Stáhnout |
| 2024-12-04 23:00:00 | 8-K | | Stáhnout |
| 2024-12-02 00:00:00 | 8-K | | Stáhnout |
| 2024-12-01 23:00:00 | 8-K | | Stáhnout |
| 2024-11-05 00:00:00 | 8-K | | Stáhnout |
| 2024-11-04 23:00:00 | 8-K | | Stáhnout |
| 2024-10-31 00:00:00 | 10-Q | | Stáhnout |
| 2024-10-30 23:00:00 | 10-Q | | Stáhnout |
| 2024-08-01 01:00:00 | 10-Q | | Stáhnout |
| 2024-08-01 00:00:00 | 10-Q | | Stáhnout |
| 2024-07-01 01:00:00 | 8-K | | Stáhnout |
| 2024-07-01 00:00:00 | 8-K | | Stáhnout |
| 2024-05-30 01:00:00 | 8-K | | Stáhnout |
| 2024-05-30 00:00:00 | 8-K | | Stáhnout |
| 2024-05-28 01:00:00 | 8-K | | Stáhnout |
| 2024-05-28 00:00:00 | 8-K | | Stáhnout |
| 2024-05-08 01:00:00 | 8-K | | Stáhnout |
| 2024-05-08 01:00:00 | 10-Q | | Stáhnout |
| 2024-05-08 00:00:00 | 8-K | | Stáhnout |
| 2024-05-08 00:00:00 | 10-Q | | Stáhnout |
| 2024-03-06 00:00:00 | 8-K | | Stáhnout |
| 2024-03-05 23:00:00 | 8-K | | Stáhnout |
| 2024-02-28 00:00:00 | 10-K | | Stáhnout |
| 2024-02-27 23:00:00 | 10-K | | Stáhnout |
| 2023-11-02 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-01 23:00:00 | 10-Q | | Stáhnout |
| 2023-08-11 01:00:00 | 8-K | | Stáhnout |
| 2023-08-11 00:00:00 | 8-K | | Stáhnout |
| 2023-08-07 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-07 00:00:00 | 10-Q | | Stáhnout |
| 2023-06-15 01:00:00 | 8-K | | Stáhnout |
| 2023-06-15 00:00:00 | 8-K | | Stáhnout |
| 2023-05-30 01:00:00 | 8-K | | Stáhnout |
| 2023-05-30 00:00:00 | 8-K | | Stáhnout |
| 2023-05-23 01:00:00 | 8-K | | Stáhnout |
| 2023-05-23 00:00:00 | 8-K | | Stáhnout |
| 2023-05-04 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-04 00:00:00 | 10-Q | | Stáhnout |
| 2023-04-17 01:00:00 | 8-K | | Stáhnout |
| 2023-04-17 00:00:00 | 8-K | | Stáhnout |
| 2023-02-28 00:00:00 | 10-K | | Stáhnout |
| 2023-02-27 23:00:00 | 10-K | | Stáhnout |
| 2023-01-09 00:00:00 | 8-K | | Stáhnout |
| 2023-01-08 23:00:00 | 8-K | | Stáhnout |
| 2023-01-06 00:00:00 | 8-K | | Stáhnout |
| 2023-01-05 23:00:00 | 8-K | | Stáhnout |
| 2022-11-03 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-02 23:00:00 | 10-Q | | Stáhnout |
| 2022-08-08 01:00:00 | 10-Q | | Stáhnout |
| 2022-08-08 00:00:00 | 10-Q | | Stáhnout |
| 2022-05-31 01:00:00 | 8-K | | Stáhnout |
| 2022-05-31 00:00:00 | 8-K | | Stáhnout |
| 2022-05-09 01:00:00 | 10-Q | | Stáhnout |
| 2022-05-09 00:00:00 | 10-Q | | Stáhnout |
| 2022-02-28 00:00:00 | 10-K | | Stáhnout |
| 2022-02-27 23:00:00 | 10-K | | Stáhnout |
| 2022-01-25 00:00:00 | 8-K | | Stáhnout |
| 2022-01-24 23:00:00 | 8-K | | Stáhnout |
| 2021-11-08 00:00:00 | 8-K | | Stáhnout |
| 2021-11-07 23:00:00 | 8-K | | Stáhnout |
| 2021-11-02 00:00:00 | 10-Q | | Stáhnout |
| 2021-11-01 23:00:00 | 10-Q | | Stáhnout |
| 2021-08-05 01:00:00 | 10-Q | | Stáhnout |
| 2021-08-05 00:00:00 | 10-Q | | Stáhnout |
| 2021-05-28 01:00:00 | 8-K | | Stáhnout |
| 2021-05-28 00:00:00 | 8-K | | Stáhnout |
| 2021-05-06 01:00:00 | 10-Q | | Stáhnout |
| 2021-05-06 00:00:00 | 10-Q | | Stáhnout |
| 2021-03-16 00:00:00 | 10-K | | Stáhnout |
| 2021-03-15 23:00:00 | 10-K | | Stáhnout |
| 2021-01-22 00:00:00 | 8-K | | Stáhnout |
| 2021-01-21 23:00:00 | 8-K | | Stáhnout |
| 2021-01-20 00:00:00 | 8-K | | Stáhnout |
| 2021-01-19 23:00:00 | 8-K | | Stáhnout |
| 2021-01-19 00:00:00 | 8-K | | Stáhnout |
| 2021-01-18 23:00:00 | 8-K | | Stáhnout |
| 2020-11-05 00:00:00 | 10-Q | | Stáhnout |
| 2020-11-04 23:00:00 | 10-Q | | Stáhnout |
| 2020-09-02 01:00:00 | 8-K | | Stáhnout |
| 2020-09-02 00:00:00 | 8-K | | Stáhnout |
| 2020-08-07 01:00:00 | 8-K | | Stáhnout |
| 2020-08-07 00:00:00 | 8-K | | Stáhnout |
| 2020-08-06 01:00:00 | 10-Q | | Stáhnout |
| 2020-08-06 00:00:00 | 10-Q | | Stáhnout |
| 2020-07-06 01:00:00 | 8-K | | Stáhnout |
| 2020-07-06 00:00:00 | 8-K | | Stáhnout |
| 2020-05-19 01:00:00 | 8-K | | Stáhnout |
| 2020-05-19 00:00:00 | 8-K | | Stáhnout |
| 2020-05-11 01:00:00 | 10-Q | | Stáhnout |
| 2020-05-11 00:00:00 | 10-Q | | Stáhnout |
| 2020-04-16 01:00:00 | 8-K | | Stáhnout |
| 2020-04-16 00:00:00 | 8-K | | Stáhnout |
| 2020-04-13 01:00:00 | 8-K | | Stáhnout |
| 2020-04-13 00:00:00 | 8-K | | Stáhnout |
| 2020-03-17 00:00:00 | 8-K | | Stáhnout |
| 2020-03-16 23:00:00 | 8-K | | Stáhnout |
| 2020-03-16 00:00:00 | 10-K | | Stáhnout |
| 2020-03-15 23:00:00 | 10-K | | Stáhnout |
| 2020-03-12 00:00:00 | 8-K | | Stáhnout |
| 2020-03-11 23:00:00 | 8-K | | Stáhnout |
| 2020-01-09 00:00:00 | 8-K | | Stáhnout |
| 2020-01-08 23:00:00 | 8-K | | Stáhnout |
